ReviewBest practice & research. Clinical obstetrics & gynaecology2012
New technologies for cervical cancer screening.
Review in Best practice & research. Clinical obstetrics & gynaecology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Trial
- Article
- Application of the hub and spokes model in improving access to cervical cancer screening in Ghana.Ghana medical journal · 2022Article
- Article
- Analysis of the application values of different combination schemes of liquid-based cytology and high-risk human papilloma virus test in the screening of high-grade cervical lesions.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018Article
- Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors.Gynecologic oncology · 2018Article
- Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes.Cancer prevention research (Philadelphia, Pa.) · 2016Article
- "Drivers" of translational cancer epidemiology in the 21st century: needs and opportunities.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
New technologies for cervical cancer screening seek to provide an accurate, efficient and cost-effective way of identifying women at risk for cervical cancer. Current screening uses human papilloma virus DNA testing combined with cytology, and requires multiple visits at a great cost to the patient and society. New methods for screening include HPV diagnostics (detection of either the presence of human papilloma virus or integration of the virus into the host cell), proliferation, and detection of epigenetic changes, either in the host or virus. These methods show promise in changing the way that current cervical cancer screening is undertaken in low-and high-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.